Core Viewpoint - First Watch Restaurant Group, Inc. announces the retirement of Chief Financial Officer Mel Hope, who will assist in the transition to his successor, ensuring continuity in financial leadership [1][2][3] Company Leadership Transition - Mel Hope has been with First Watch since 2018 and has played a crucial role in guiding the company through its IPO and various growth phases [2] - The company is actively seeking both internal and external candidates for the CFO position, with Hope expected to remain until a successor is appointed [1][2] Company Overview - First Watch is recognized as a leading Daytime Dining concept, specializing in made-to-order breakfast, brunch, and lunch using fresh ingredients [3] - The company operates over 630 restaurants across 32 states and has received multiple awards, including 1 Best Breakfast by Newsweek's Readers' Choice Awards 2025 [3] - First Watch has a commitment to community impact, having raised approximately $2.0 million through donations linked to children's meals served [3]

Core Insights - Xometry, Inc. reported a record revenue growth of 30% year-over-year in Q4 2025, reaching $192 million, driven by strong enterprise customer adoption of its supply chain solutions [2][5] - The company achieved a gross profit increase of 27% year-over-year to $75.2 million, with Adjusted EBITDA improving by $7.3 million to $8.4 million [2][5] - For the full year 2025, Xometry's marketplace revenue was $630 million, reflecting a 30% increase year-over-year, while services revenue decreased by 4% to $57 million [8][7] Financial Highlights - Q4 2025 revenue was $192 million, a 30% increase from $148.5 million in Q4 2024 [10] - Q4 gross profit rose to $75.2 million, up 27% from $59 million in the same quarter last year [10] - Adjusted EBITDA for Q4 2025 was $8.4 million, compared to $1.05 million in Q4 2024, marking a 699% increase [10] - Full year 2025 net loss attributable to common stockholders was $61.7 million, compared to a loss of $50.4 million in 2024 [10] Business Highlights - Active Buyers increased by 20% year-over-year, reaching 81,821 as of December 31, 2025 [6] - Marketplace revenue for Q4 2025 was $178 million, a 33% increase year-over-year, while services revenue was $13.9 million, a slight decrease of 1% [6][10] - The number of Active Suppliers grew by 17% year-over-year to 4,996, with a focus on larger suppliers to meet enterprise customer needs [6][11] Operational Developments - Xometry launched performance-based listings on Thomasnet, enhancing supplier visibility and engagement [6] - The company expanded its platform with new high-performance materials critical for industries such as aerospace and medical devices [8] - Xometry achieved Cybersecurity Maturity Model Certification (CMMC Level 2), reinforcing its position in the aerospace and defense sectors [11] Future Outlook - For Q1 2026, Xometry expects revenue between $187 million and $189 million, representing a growth of 24-25% year-over-year [15] - The company anticipates continued incremental Adjusted EBITDA margins of at least 20% as it scales towards $1 billion in revenue [2][18]

Core Viewpoint - Xometry, Inc. announces a leadership transition with Sanjeev Singh Sahni succeeding Randy Altschuler as CEO effective July 1, 2026, while Altschuler will take on the role of Executive Chair of the Board [1][2]. Leadership Transition - Randy Altschuler, co-founder and current CEO, will transition to Executive Chair, emphasizing the company's strong position for leadership change [1][2]. - Sanjeev Singh Sahni, currently the President, has been instrumental in Xometry's revenue growth and profitability, making him a suitable successor [2][3]. Company Performance - Xometry reported record results in 2025, indicating significant progress in digitizing the global manufacturing market since its founding in 2013 [2]. - The company is on a clear and increasingly profitable trajectory, which supports the timing of the leadership transition [2]. Future Direction - Altschuler will focus on strategic growth initiatives and key corporate partnerships in his new role, maintaining a founder's perspective at the Board level [2]. - Sahni expressed excitement about leading the company during a pivotal moment, aiming to accelerate product-led growth and solidify Xometry's position in the custom manufacturing marketplace [3]. Company Overview - Xometry operates an AI-native marketplace and offers a suite of cloud-based services that are digitizing the manufacturing industry, providing critical resources for manufacturers and streamlining procurement processes for buyers [4].

Full-year 2025 net product revenues of $689 million SYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102 million Regulatory submission for SYFOVRE prefilled syringe planned for the first half of 2026EMPAVELI franchise has strong momentum with successful launch in C3G and primary IC-MPGN, and pivotal trials underway in FSGS and DGFCash and cash equivalents of $466 million as of December 31, 2025; projected re ...

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026 Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD); U.S. Biologics License Appl ...

Highlights: Ongwe secures contiguous license area, increasing the size of the Omatjete project area by up to 42%.Ongwe now controls 50km of strike on the Okondeka Fault Zone (OFZ) which hosts the Kokoseb deposit (WIA Gold) and the newly discovered Manga Gold Prospect.New structural interpretation reveals prospective transfer structures and parallel Okakongo Fault Zone in new licence area. VANCOUVER, British Columbia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Ongwe Minerals Inc. (TSXV:OGW) (“Ongwe” or “the Company”) ...

ALACHUA, Fla. and TAMPA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter Financial Results Fourth quarter 2025 revenue was $59.9 million, a 21.3% increase compared to the fourth quarter 2024 revenue, and a 0.3% decrease over the thir ...

MONTVALE, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the JP Morgan Consumer Ingredients Forum on March 10, 2026. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer and Allison Baurichter, Senior Director Investor Relations will participate in the conference. About Balchem Corporation Balchem Corporati ...

Core Insights - Iovance Biotherapeutics announced positive early data from a pilot clinical trial of lifileucel, showing a 50% Objective Response Rate (ORR) in patients with advanced undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS) who were refractory to prior therapies [1][2] Company Overview - Iovance Biotherapeutics focuses on developing novel tumor infiltrating lymphocyte (TIL) therapies for cancer patients, aiming to be a leader in this field [5] - The company has demonstrated promising clinical data across multiple solid tumors and is committed to continuous innovation in cell therapy [5] Clinical Trial Results - Among the first six evaluable patients treated with lifileucel, the confirmed ORR was 50%, with patients showing deep responses that improved over time [2] - The mean sum of diameters of tumors at baseline was 117 millimeters, and patients had undergone more than two prior lines of therapy [2] - The safety profile of lifileucel was favorable and consistent with its use in other indications [2] Market Opportunity - There are over 8,000 patients diagnosed annually with UPS and DDLPS in the U.S. and Europe, highlighting a significant market opportunity [1] - UPS and DDLPS are aggressive sarcomas with poor prognosis, affecting more than 3,000 patients in the U.S. and over 5,000 in Europe each year [3] Unmet Medical Need - Current treatment options for second-line patients are limited, with recent studies reporting ORRs of less than 5% and median overall survival of approximately 9-10 months [3] - Lifileucel has the potential to address this unmet need, as there are currently no approved immunotherapy options for these patients [4] Future Plans - Iovance plans to initiate a single-arm registrational trial for lifileucel in second-line advanced UPS and DDLPS in Q2 2026 and will engage with the FDA for expedited approval [2] - The company also aims to explore lifileucel in other high-grade soft tissue sarcoma subtypes with high unmet need [2]

BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in several upcoming investor conferences in March 2026. TD Cowen 46th Annual Health Care Conference:Date: Monday, March 2, 2026Fireside Chat: 9:10 – 9:40 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Boston, MA Jefferies Biotech on the ...